Sana Biotechnology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Operating expenses | $250.3M | $272.7M | $293.1M | $272.6M | $356.9M |
| Cash from operations | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$251.1M |
| Capital expenditure | $938,000 | $33.4M | $20.0M | $20.9M | $29.9M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$280.9M |
| Impairments | $44.6M | $1.9M | $7.0M | $0 | $0 |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.1B |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
Shares outstanding 278.3M · Free float 66.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.